Author

Jaymes Fuller

Observed names: Fuller, Jaymes L, J. Fuller, Jaymes L. Fuller

Institutions: Seton Hall University, Bristol-Myers Squibb (United States)

Observed institutions: Seton Hall University, Bristol-Myers Squibb (United States), Celgene (United States)

ORCID: 0009-0002-8772-0897

Observed ORCID: 0009-0002-8772-0897

OpenAlex ID: A5035932012

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

2023 · Yi Lin, Noopur S. Raje, et al. · Nature Medicine · 127

Zinc chloride affects chondrogenesis via VEGF signaling

2021 · Sarah Hozain, Alexis Hernandez, et al. · Experimental Cell Research · 25

Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma

2020 · Julie Rytlewski, Deepu Madduri, et al. · Blood · 25

Methodology and Characterization of a 3D Bone Organoid Model Derived from Murine Cells

2024 · Jaymes Fuller, Katherine Sares Lefferts, et al. · International Journal of Molecular Sciences · 17

Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma (RRMM) patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T cell therapy.

2022 · Julie Rytlewski, Jaymes Fuller, et al. · Journal of Clinical Oncology · 11

P866: Correlative Analysis to Define Patient Profiles Associated With Manufacturing and Clinical Endpoints in Relapsed/refractory Multiple Myeloma Patients Treated With Idecabtagene Vicleucel (bb2121)

2022 · J. Rytlewski, J. Fuller, et al. · HemaSphere · 8

The Role of T Lymphocytes in Bone Remodeling

2023 · Jaymes L. Fuller, Renee E. Samuel, et al. · Open Journal of Orthopedics · 3

Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma

2019 · Ethan G. Thompson, Yue Jiang, et al. · Blood · 3

Preapheresis clinical patient profiles predict patient’s manufacturing fitness and efficacy with idecabtagene vicleucel

2026 · Julie Rytlewski, Doris K. Hansen, et al. · Blood Immunology & Cellular Therapy · 2

P-019: Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma patients treated with idecabtagene vicleucel (ide-cel)

2022 · Julie Rytlewski, Jaymes Fuller, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

T cell Associated Cytokines Influence Bone Metabolism in A Glucose Dependent Manner: Implications for Fracture Healing in Type 1 Diabetes Mellitus

2026 · Fuller, Jaymes L · Seton Hall University eRepository (Seton Hall University)

CAR T manufacturing: process modifications for a transformational autologous product on a rapid path to licensure

2018 · Thomas A. Brieva, Seth G. Jones, et al.

Works count: 12

Citation count: 222

H-index: 6

I10-index: 5